Pacritinib hydrochloride

Modify Date: 2024-01-14 08:36:53

Pacritinib hydrochloride structure	Common Name	Pacritinib hydrochloride
	CAS Number	1228923-43-0	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₈H₃₂N₄O_3.xClH	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Pacritinib hydrochloride

Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3].

Name	Pacritinib hydrochloride

Description	Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK
Target	JAK2V617F:19 nM (IC50) JAK3:520 nM (IC50) JAK1:1280 nM (IC50) JAK2wt:23 nM (IC50) Tyk2:50 nM (IC50)
References	[1]. Hart S, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011 Nov;25(11):1751-9. [2]. Hart S, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011 Nov;1(11):e44. [3]. Komrokji RS, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649-55.

Molecular Formula	C₂₈H₃₂N₄O_3.xClH

Pacritinib hydrochloride

Use of Pacritinib hydrochloride

Names

Pacritinib hydrochloride Biological Activity

Chemical & Physical Properties